Sign up
Pharma Capital

Friday Night shares up as subsidiary Spire to provide its expertise to Canadian provincial government

Friday Night Inc shares shot up over 11% on the news...
1523548600_canadian-flag-1.jpg
The new subsidiary is to provide strategic advice and expertise to a Canadian provincial government

Cannabis- focused Friday Night Inc (CSE:TGIF, OTCQB:TGIFF) saw shares shoot up 11% Thursday on the back of an announcement about its new acquisition Spire Secure Logistics and Canada.

In late February, the group said it had acquired Spire, which specializes in security and has expertise in the cannabis industry. It closed the deal in March.

Spire is led by experts with international backgrounds in covert and undercover operations to infiltrate and disrupt organized crime, including cartels and other violent gangs.

The new subsidiary is to provide strategic advice and expertise to a Canadian provincial government on security programs and infrastructure for the legal distribution and sale of cannabis, Friday Night said.

"We are pleased to be developing secure and compliant strategies and programs as Canadian provinces and cities begin to implement legal cannabis distribution and sales," said Friday Night director and Spire CEO Andrew Richards.

Friday Night also announced today the appointment of  Kevin Mead as chief administration officer and director of International programs at Spire.

Mead is a 23-year career veteran of the Canadian Army and has served in numerous command, training and senior staff positions at tactical, operational and strategic levels.

Friday Night is a rapidly growing firm in the legal cannabis space.

It owns the first licensed cultivation facility in the Las Vegas area, Alternative Medicine Association (AMA), as well as the developer of hemp and cannabidiol (CBD) infused product maker called Infused Mfg.

Shares in Toronto added 11.34% to stand at C$0.54.



Register here to be notified of future Company articles
View full profile View Profile
View All

© biotech Capital 2018

Biotech Capital, a subsidiary of Proactive Investors, acts as the vanguard for listed biotech companies to interact with institutional and highly capitalised investors.
Headquartered in London, Biotech Capital is led by a team of Europe's leading analysts and journalists, publishing daily content, covering all key movements in the Biotechnology market.